title: Molecular targeted therapies for rhabdomyosarcoma: focus on hedgehog and apoptosis signaling.
abstract: Dysfunction of cell death and proliferation pathways can contribute to rhabdomyosarcomagenesis, tumor progression and treatment resistance. Therefore, the identification of key signaling hubs and molecules that govern the decision between life and death of a cancer cell is expected to open new perspectives for drug discovery. For example, programmed cell death pathways can be engaged in rhabdomyosarcoma (RMS) cells by recombinant soluble proteins, monoclonal antibodies or small-molecule inhibitors. In addition, the hedgehog (Hh) cascade is often aberrantly activated in RMS and represents a promising target for therapeutic intervention. The development of molecular targeted cancer therapeutics will likely lead to more effective treatment options for patients with RMS.
authors.affiliation: Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Frankfurt a. Main, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Fulda
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics*; D002648:Child; D004195:Disease Models, Animal; D018450:Disease Progression; D055808:Drug Discovery; D019008:Drug Resistance, Neoplasm; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics; D053823:Hedgehog Proteins / Q000235:genetics*; D006801:Humans; D051379:Mice; D058990:Molecular Targeted Therapy / Q000379:methods*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000187:drug effects* / Q000235:genetics*; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000187:drug effects* / Q000235:genetics*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000235:genetics*; D015398:Signal Transduction / Q000187:drug effects* / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D053823:Hedgehog Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D011994:Recombinant Proteins